NASDAQ$PTGX
Protagonist Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported third quarter financial results and provided a corporate update.
Protagonist Therapeutics reported its financial results for the third quarter ended September 30, 2020. The company's clinical assets PTG-300, PN-943 and PTG-200, are progressing in Phase 2 clinical proof-of-concept studies. Two additional oral interleukin-23 receptor antagonists, PN-235 and PN-232, were selected for advancement into clinical development in collaboration with Janssen.
- PTG-300, PN-943 and PTG-200 continue to make progress in Phase 2 clinical proof-of-concept studies.
- Updated clinical data from Phase 2 study of PTG-300 in patients with polycythemia vera will be shared in December.
- Ongoing Phase 2 clinical programs with PN-943 in patients with ulcerative colitis, and PTG-200 in patients with Crohn’s disease are moving forward.
- Two additional oral interleukin-23 receptor antagonists, PN-235 and PN-232, were selected for advancement into clinical development in collaboration with Janssen.
Headline financials
Revenue & EPS history
Protagonist · Revenue · Quarterly
$13.1M
Forward guidance
The press release contains forward-looking statements regarding the potential of product candidates to improve standards of care, the ability to fund operations into future periods, and expectations regarding the timing of the initiation of clinical trials.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+3.2%
Avg return
Earnings day
+5.4%
Avg return
5 days after
+8.3%
Avg return
30 days after
51%
20 / 39 earnings
Positive
+75.1%
Q1 2020
Best reaction
-21.2%
Q1 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.3% | -0.2% | +3.3% | |
| Q4 2025 | -0.3% | +7.8% | +13.3% | |
| Q3 2025 | -0.2% | +6.4% | +12.4% | |
| Q1 2025 | +2.4% | +3.2% | +22.9% | |
| Q4 2024 | -7.1% | -6.2% | +35.6% | |
| Q3 2024 | -2.9% | -9.3% | -11.6% | |
| Q2 2024 | +0.0% | +8.2% | +17.4% | |
| Q1 2024 | +4.0% | +8.3% | +30.5% | |
| Q4 2023 | +3.0% | +8.9% | -2.0% | |
| Q3 2023 | +10.2% | +9.0% | +22.8% | |
| Q2 2023 | +3.3% | -2.0% | +5.2% | |
| Q1 2023 | +1.5% | +3.3% | +15.3% | |
| Q4 2022 | -8.4% | -9.9% | -25.9% | |
| Q3 2022 | -0.5% | +9.4% | +0.4% | |
| Q2 2022 | +2.2% | -1.6% | -21.1% | |
| Q1 2022 | -0.3% | -10.3% | -6.4% | |
| Q4 2021 | +7.2% | -0.7% | -2.3% | |
| Q3 2021 | +5.0% | +7.4% | +0.1% | |
| Q2 2021 | -2.2% | -0.4% | -0.8% | |
| Q1 2021 | -0.4% | -0.1% | +19.3% | |
| Q4 2020 | +3.5% | +2.8% | -11.4% | |
| Q3 2020 | +14.2% | +6.6% | +11.0% | |
| Q2 2020 | +8.3% | +2.3% | +23.8% | |
| Q1 2020 | +75.1% | +97.4% | +98.0% | |
| Q4 2019 | -4.8% | +5.1% | -7.6% | |
| Q3 2019 | -19.3% | -14.2% | -37.5% | |
| Q2 2019 | +0.8% | -2.9% | +60.6% | |
| Q1 2019 | +20.8% | +16.3% | +31.4% | |
| Q4 2018 | +0.1% | +22.3% | +22.2% | |
| Q3 2018 | +14.1% | +22.3% | -14.6% | |
| Q2 2018 | -1.8% | -6.4% | -18.1% | |
| Q1 2018 | -21.2% | -22.4% | -13.5% | |
| Q4 2017 | -2.0% | +1.4% | -57.5% | |
| Q3 2017 | +8.9% | +16.2% | +25.2% | |
| Q2 2017 | -7.7% | -4.4% | +33.6% | |
| Q1 2017 | +10.5% | +14.3% | +21.1% | |
| Q4 2016 | -0.6% | +0.4% | -16.8% | |
| Q3 2016 | -1.6% | +3.4% | -16.5% | |
| Q2 2016 | +9.4% | +19.1% | +63.8% | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro